GLP3-RT

The triple-pathway metabolic candidate

Listed strength: 20 mg
Mol. weight: ≈4731 g/mol
Residues: 39
Class: Triple incretin agonist (GIP/GLP-1/GcgR)

20 mg lyophilized vial$6.00/mg · research use only

Reference specifications publishedResearch use only

Research use only · no human or veterinary use, consumption, administration, diagnosis, treatment, prevention, cosmetic use, or food use. Sold to qualified laboratory and analytical users.

01 / What it is

GLP3-RT is an investigational single-molecule triple agonist that activates the GIP, GLP-1, and glucagon receptors at once. It represents the newest generation of incretin-based research compounds, extending the dual-agonist approach with a third metabolic pathway.

02 / Mechanism in the literature

By engaging all three receptors simultaneously, GLP3-RT is studied across insulin-signaling, appetite-signaling, and energy-expenditure research. The added glucagon-receptor activity is of particular research interest for its role in hepatic and metabolic-rate pathways.

03 / Research context

GLP3-RT appears in metabolic and incretin literature exploring body-composition and energy-balance models. It is handled strictly as a research material.

Listed format20 mg lyophilized vial

Sequence39-residue triple agonist

Molecular formulaNot a discrete formula

Molecular weight≈4731 g/mol

Catalogue referenceAGX-01

Listed price$120

StatusInvestigational research compound

04 / Common questions

What does 'triple agonist' mean?

One molecule activates three different receptors — here GIP, GLP-1, and the glucagon receptor — rather than a single target.

Is GLP3-RT approved for use?

No. It is an investigational compound supplied for laboratory research use only, with no human or animal-use indication.